TuisM1RN34 • BVMF
add
Moderna Inc Bdr
Vorige sluiting
R$34,29
Dagwisseling
R$32,88 - R$34,19
Jaarwisseling
R$16,70 - R$44,00
Markkapitalisasie
47,54 mjd USD
Gemiddelde volume
21,98 k
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Inkomste | 167,00 m | -91,03% |
Bedryfskoste | 274,00 m | -10,16% |
Netto inkomste | -1,18 mjd | -1 587,34% |
Netto winsgrens | -703,59 | -16 694,10% |
Wins per aandeel | -3,07 | -1 715,79% |
EBITDA | -1,23 mjd | -327,08% |
Effektiewe belastingkoers | -0,86% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 8,52 mjd | -4,48% |
Totale bates | 16,73 mjd | -30,66% |
Totale aanspreeklikheid | 3,91 mjd | -25,66% |
Totale ekwiteit | 12,82 mjd | — |
Uitstaande aandele | 383,24 m | — |
Prys om te bespreek | 1,02 | — |
Opbrengs op bates | -18,01% | — |
Opbrengs op kapitaal | -21,71% | — |
Kontantvloei
Netto kontantverandering
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -1,18 mjd | -1 587,34% |
Kontant van bedrywe | -989,00 m | 19,27% |
Kontant van beleggings | 118,00 m | -94,13% |
Kontant van finansiering | 14,00 m | 102,58% |
Netto kontantverandering | -857,00 m | -451,23% |
Beskikbare kontantvloei | -845,00 m | 33,64% |
Meer oor
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. Wikipedia
Gestig
Sep. 2010
Webwerf
Werknemers
5 600